Trial Profile
From Immediate-Release MPH to OROS MPH: The Impact Upon Family of Children and Adolescents With ADHD.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Oct 2015
Price :
$35
*
At a glance
- Drugs Methylphenidate (Primary)
- Indications Attention-deficit hyperactivity disorder
- Focus Therapeutic Use
- Sponsors Johnson & Johnson
- 07 Apr 2014 Primary endpoints were added as reported by ClinicalTrials.gov record.
- 28 Apr 2010 Actual patient number (297) added as reported by ClinicalTrials.gov.
- 10 Jun 2009 Actual end date (Jun 2008) added as reported by ClinicalTrials.gov.